# A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate

> **NCT03740373** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 10 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold
- **DRUG:** BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold

## Key facts

- **NCT ID:** NCT03740373
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-04
- **Primary completion:** 2018-10-11
- **Final completion:** 2018-10-11
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03740373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03740373, "A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03740373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*